LONDON (Alliance News) - GlaxoSmithKline PLC and Theravance Inc Wednesday announced positive results for two late stage studies of Incruse Ellipta when combined with Relvar Breo Ellipta for the treatment of chronic obstructive pulmonary disease.
The two phase III studies using the combined treatment showed a "statistically significant" improvement in lung function compared with patients treated with Relvar Breo Ellipta and a placebo.
The company said the studies were the first to investigate the combined effect of two of the newest medicines in its respiratory portfolio. It will continue to progress its research on the combined treatments as a potential new treatment approach.
"These data are an important addition to the evidence base supporting the efficacy and safety of Incruse," said Head of Glaxo's Global Respiratory Franchise Darrell Baker in a statement.
Shares in Glaxo were trading up 0.3% at 1,609.50 pence Wednesday afternoon.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2014 Alliance News Limited. All Rights Reserved.
Glaxosmithkline (GSK)
